The ESMO Targeted Anticancer Therapies Asia Congress 2026 will take place from 12 to 14 June 2026 in Hong Kong SAR, China. Congress resources will be available post-event on OncologyPRO.

Learning objectives

Educational and Special sessions, a Keynote address, and a rich abstract programme will provide attendees insights on:

1. New methodologies for preclinical discovery and early phase drug development, including AI

2. Breakthroughs in novel kinase inhibitors, next-generation immunotherapies, antibody-drug conjugates, multispecifics and cell-based therapies

3. Challenges and opportunities in building a research ecosystem of innovation and value in cancer drug development

4. Multi stakeholder perspectives from the oncology and biotechnology industries

Audience

The ESMO TAT Asia programme will be of interest to persons working in academia, industry, and regulatory agencies engaged in the discovery and early clinical development of novel anticancer therapies, including, but not limited to, preclinical scientists, clinicians, methodological experts, legal and regulatory affairs specialists, industry investigators and executives, other professionals active in anticancer drug development, and patient advocates. The programme will be of educational value to oncologists, haematologists, pathologists and organ system specialists, with a unique osmosis between academia and industry.

For registration:

https://www.esmo.org/meeting-calendar/esmo-targeted-anticancer-therapies-asia-congress-2026/registration